INTRODUCTION: Approximately 50% of lung cancer patients with epidermal growth factor receptor (EGFR)-mutations (deletion in exon 19 or L858R) who develop acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) reportedly carry a secondary EGFR T790M mutation. This mutation has been suggested to be present in tumor cells before EGFR-TKI treatment in a small population of individuals. Here, we use a highly sensitive colony hybridization technique in an attempt to evaluate the actual incidence of T790M in pretreatment tumor specimens. METHODS: DNA was extracted from surgically resected tumor tissues of 38 patients with the EGFR mutation and examined for the presence of T790M, using a standard polymerase chain reaction based method followed by a modified colony hybridization (CH) technique with an analytical sensitivity of approximately 0.01%. Associations between the T790M status and clinical characteristics including time to treatment failure (TTF) for EGFR-TKI were evaluated. RESULTS: The T790M mutation analysis of the specimens from the 38 patients detected 30 mutants (79%). The median TTF was 9 months for the patients with pretreatment T790M and 7 months for the patients without the T790M mutation (p = 0.44). When the patients with T790M were divided into strongly positive and modestly positive subgroups in terms of the frequency of positive signals observed using CH technique, the 7 patients with strong positivity had a TTF that was significantly longer than that of the 8 patients without T790M (p = 0.0097) and of the 23 patients with modest positivity (p = 0.0019). CONCLUSIONS: Our highly sensitive CH method showed that a subgroup of non-small-cell lung cancer patients with the EGFR mutation harbored the rare T790M allele before EGFR-TKI treatment. A high proportion of T790M allele may define a clinical subset with a relatively favorable prognosis.
INTRODUCTION: Approximately 50% of lung cancerpatients with epidermal growth factor receptor (EGFR)-mutations (deletion in exon 19 or L858R) who develop acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) reportedly carry a secondary EGFRT790M mutation. This mutation has been suggested to be present in tumor cells before EGFR-TKI treatment in a small population of individuals. Here, we use a highly sensitive colony hybridization technique in an attempt to evaluate the actual incidence of T790M in pretreatment tumor specimens. METHODS: DNA was extracted from surgically resected tumor tissues of 38 patients with the EGFR mutation and examined for the presence of T790M, using a standard polymerase chain reaction based method followed by a modified colony hybridization (CH) technique with an analytical sensitivity of approximately 0.01%. Associations between the T790M status and clinical characteristics including time to treatment failure (TTF) for EGFR-TKI were evaluated. RESULTS: The T790M mutation analysis of the specimens from the 38 patients detected 30 mutants (79%). The median TTF was 9 months for the patients with pretreatment T790M and 7 months for the patients without the T790M mutation (p = 0.44). When the patients with T790M were divided into strongly positive and modestly positive subgroups in terms of the frequency of positive signals observed using CH technique, the 7 patients with strong positivity had a TTF that was significantly longer than that of the 8 patients without T790M (p = 0.0097) and of the 23 patients with modest positivity (p = 0.0019). CONCLUSIONS: Our highly sensitive CH method showed that a subgroup of non-small-cell lung cancerpatients with the EGFR mutation harbored the rare T790M allele before EGFR-TKI treatment. A high proportion of T790M allele may define a clinical subset with a relatively favorable prognosis.
Authors: Yang Yang; Yi Meng; Hang Zhang; Xiaoyan Shen; Rutian Li; Lixia Yu; Baorui Liu; Lifeng Wang Journal: Oncol Lett Date: 2017-12-19 Impact factor: 2.967
Authors: M Cabanero; R Sangha; B S Sheffield; M Sukhai; M Pakkal; S Kamel-Reid; A Karsan; D Ionescu; R A Juergens; C Butts; M S Tsao Journal: Curr Oncol Date: 2017-04-27 Impact factor: 3.677
Authors: Kenichi Suda; Paul A Bunn; Christopher J Rivard; Tetsuya Mitsudomi; Fred R Hirsch Journal: J Thorac Oncol Date: 2016-09-15 Impact factor: 15.609
Authors: David F Heigener; Christian Schumann; Martin Sebastian; Parvis Sadjadian; Ingo Stehle; Angela Märten; Anne Lüers; Frank Griesinger; Matthias Scheffler Journal: Oncologist Date: 2015-09-09
Authors: Tomasz Powrózek; Paweł Krawczyk; Bożena Jarosz; Radosław Mlak; Kamila Wojas-Krawczyk; Marek Sawicki; Dariusz Stencel; Tomasz Trojanowski; Janusz Milanowski Journal: Pathol Oncol Res Date: 2014-05-03 Impact factor: 3.201
Authors: Ugur Hodoglugil; Michelle W Carrillo; Joan M Hebert; Niki Karachaliou; Rafael C Rosell; Russ B Altman; Teri E Klein Journal: Pharmacogenet Genomics Date: 2013-11 Impact factor: 2.089
Authors: Vincent L Cannataro; Stephen G Gaffney; Carly Stender; Zi-Ming Zhao; Mark Philips; Andrew E Greenstein; Jeffrey P Townsend Journal: Oncogene Date: 2018-02-16 Impact factor: 9.867